Aliases & Classifications for Hypoxia

MalaCards integrated aliases for Hypoxia:

Name: Hypoxia 53 17 70

Classifications:



External Ids:

UMLS 70 C0242184

Summaries for Hypoxia

Novus Biologicals : 55 Hypoxia is a pathological condition in which the body as a whole (generalized hypoxia) or region of the body (tissue hypoxia) is deprived of adequate oxygen supply. Hypoxia contributes significantly to the pathophysiology of major categories of human disease, including myocardial and cerebral ischemia, cancer, pulmonary hypertension, congenital heart disease and chronic obstructive pulmonary disease. Hypoxia inducible factor-1 (HIF-1) is a transcription factor that regulates adaptive responses to a lack of oxygen in mammalian cells. HIF-1 consists of two proteins, HIF-1 alpha and HIF-1 beta. HIF-1 alpha accumulates under hypoxic conditions whereas HIF-1 beta is constitutively expressed. HIF-1 alpha is an important mediator of the hypoxic response of tumor cells and controls the up-regulation of a number of factors important for solid tumor expansion including the angiogenic factor VEGF.

MalaCards based summary : Hypoxia is related to chronic mountain sickness and renal cell carcinoma, nonpapillary, and has symptoms including seizures, fever and dyspnea. An important gene associated with Hypoxia is KMT2A (Lysine Methyltransferase 2A), and among its related pathways/superpathways are CDK-mediated phosphorylation and removal of Cdc6 and Pathways in cancer. The drugs Bosentan and Succinylcholine have been mentioned in the context of this disorder. Affiliated tissues include endothelial, smooth muscle and prostate, and related phenotypes are Decreased viability and Decreased viability

NINDS : 53 Cerebral hypoxia refers to a condition in which there is a decrease of oxygen supply to the brain even though there is adequate blood flow. Drowning, strangling, choking, suffocation, cardiac arrest, head trauma, carbon monoxide poisoning, and complications of general anesthesia can create conditions that can lead to cerebral hypoxia. Symptoms of mild cerebral hypoxia include inattentiveness, poor judgment, memory loss, and a decrease in motor coordination. Brain cells are extremely sensitive to oxygen deprivation and can begin to die within five minutes after oxygen supply has been cut off. When hypoxia lasts for longer periods of time, it can cause coma, seizures, and even brain death.  In brain death, there is no measurable activity in the brain, although cardiovascular function is preserved. Life support is required for respiration.

Wikipedia : 73 Hypoxia is a condition in which the body or a region of the body is deprived of adequate oxygen supply... more...

Related Diseases for Hypoxia

Diseases related to Hypoxia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1474)
# Related Disease Score Top Affiliating Genes
1 chronic mountain sickness 31.9 VEGFA EPAS1 EGLN3
2 renal cell carcinoma, nonpapillary 31.5 VHL VEGFA HIF1AN HIF1A EPAS1 EGLN3
3 acute mountain sickness 31.3 VHL VEGFA HIF1AN HIF1A EGLN1
4 polycythemia 30.9 VHL VEGFA HIF1A EPAS1 EGLN3 EGLN2
5 kidney cancer 30.9 VHL VEGFA HIF1A EPAS1 CA9
6 pheochromocytoma 30.8 VHL VEGFA HIF1A EPAS1 EGLN3 EGLN2
7 soft tissue sarcoma 30.7 VEGFA HIF1A
8 clear cell renal cell carcinoma 30.7 VHL VEGFA HIF1A EPAS1 EGLN3 CA9
9 paraganglioma 30.6 VHL HIF1A EPAS1 EGLN1
10 hemangioblastoma 30.4 VHL VEGFA HIF1A EPAS1
11 von hippel-lindau syndrome 30.3 VHL VEGFA HIF1A
12 ductal carcinoma in situ 30.3 VEGFA HIF1A CA9
13 fumarate hydratase deficiency 30.2 VHL HIF1A
14 erythrocytosis, familial, 2 30.1 VHL HIF1AN HIF1A EPAS1 EGLN3 EGLN2
15 renal cell carcinoma, papillary, 1 30.0 VHL VEGFA HIF1A CA9
16 pheochromocytoma-paraganglioma 30.0 VHL EGLN2 EGLN1
17 gastrointestinal stromal tumor 30.0 VEGFA HIF1A EPAS1 EP300
18 primary polycythemia 29.9 VHL HIF1A EPAS1 EGLN3 EGLN2 EGLN1
19 acquired polycythemia 29.7 EPAS1 EGLN1
20 clear cell papillary renal cell carcinoma 29.7 VHL CA9
21 retinal hemangioblastoma 29.7 VHL VEGFA HIF1A EPAS1
22 cerebral hypoxia 11.7
23 anoxia 11.4
24 neonatal hypoxic and ischemic brain injury 11.3
25 pulmonary hypertension owing to lung disease and/or hypoxia 11.2
26 asphyxia neonatorum 11.1
27 exudative vitreoretinopathy 1 11.1
28 polycythemia due to hypoxia 11.1
29 pulmonary hypertension 11.0
30 pulmonary edema 11.0
31 sleep apnea 11.0
32 methemoglobinemia due to deficiency of methemoglobin reductase 11.0
33 respiratory underresponsiveness to hypoxia and hypercapnia 10.9
34 apnea of prematurity 10.9
35 ischemia 10.9
36 severe acute respiratory syndrome 10.9
37 hantavirus pulmonary syndrome 10.9
38 congenital extrahepatic portosystemic shunt 10.9
39 tempi syndrome 10.9
40 pneumothorax, primary spontaneous 10.8
41 methemoglobinemia and ambiguous genitalia 10.8
42 exudative vitreoretinopathy 2, x-linked 10.8
43 exudative vitreoretinopathy 4 10.8
44 tricuspid atresia 10.8
45 exudative vitreoretinopathy 5 10.8
46 exudative vitreoretinopathy 6 10.8
47 exudative vitreoretinopathy 7 10.8
48 leukostasis 10.8
49 congenital laryngeal palsy 10.8
50 typical congenital nemaline myopathy 10.8

Graphical network of the top 20 diseases related to Hypoxia:



Diseases related to Hypoxia

Symptoms & Phenotypes for Hypoxia

UMLS symptoms related to Hypoxia:


seizures; fever; dyspnea; vertigo; hemoptysis; cachexia; apnea; headache; syncope; cyanosis; edema; chills; icterus; signs and symptoms; signs and symptoms, digestive; hot flushes; cheyne-stokes respiration; coughing; hoarseness; increased sweating; anoxemia; signs and symptoms, respiratory; sneezing; hyperoxia; motor symptom; skin symptoms; physical symptom; physical appearance, body

GenomeRNAi Phenotypes related to Hypoxia according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00221-A-1 9.7 VHL
2 Decreased viability GR00221-A-2 9.7 EGLN3 EP300 VHL
3 Decreased viability GR00240-S-1 9.7 PSMA7
4 Decreased viability GR00249-S 9.7 ARNT CITED2 EGLN3 PSMA7 VEGFA VHL
5 Decreased viability GR00301-A 9.7 EGLN3 VHL
6 Decreased viability GR00381-A-1 9.7 EGLN2 EGLN3 HIF1AN PSMA7
7 Decreased viability GR00386-A-1 9.7 ARNT TIGAR
8 Decreased viability GR00402-S-2 9.7 EGLN1 EGLN3 HIF3A KMT2A PSMA7

MGI Mouse Phenotypes related to Hypoxia:

46 (show all 17)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.41 ARNT CITED2 EGLN1 EGLN2 EGLN3 EP300
2 homeostasis/metabolism MP:0005376 10.37 ARNT CITED2 EGLN1 EGLN2 EGLN3 EP300
3 hematopoietic system MP:0005397 10.36 ARNT CA9 CITED2 EGLN1 EGLN2 EGLN3
4 cellular MP:0005384 10.34 ARNT EGLN1 EGLN2 EGLN3 EP300 HIF1A
5 immune system MP:0005387 10.32 ARNT CA9 CITED2 EGLN1 EGLN2 EGLN3
6 embryo MP:0005380 10.26 ARNT CITED2 EGLN1 EGLN2 EGLN3 EP300
7 craniofacial MP:0005382 10.25 ARNT CITED2 EGLN1 EGLN2 EGLN3 EP300
8 mortality/aging MP:0010768 10.21 ARNT CA9 CITED2 EGLN1 EGLN3 EP300
9 integument MP:0010771 10.11 ARNT EGLN1 EGLN2 EGLN3 HIF1A HIF1AN
10 liver/biliary system MP:0005370 10.1 ARNT EGLN1 EGLN2 EGLN3 EPAS1 HIF1A
11 muscle MP:0005369 10.1 EGLN1 EGLN2 EGLN3 EP300 EPAS1 HIF1A
12 digestive/alimentary MP:0005381 10.08 CA9 CITED2 EP300 HIF1A TIGAR VEGFA
13 limbs/digits/tail MP:0005371 9.98 CITED2 EGLN2 EGLN3 HIF1A KMT2A VEGFA
14 normal MP:0002873 9.81 ARNT CITED2 EGLN3 EP300 HIF1A HIF1AN
15 neoplasm MP:0002006 9.8 ARNT EP300 HIF1A KMT2A TIGAR VEGFA
16 renal/urinary system MP:0005367 9.61 ARNT CITED2 EGLN1 EP300 HIF1A KMT2A
17 respiratory system MP:0005388 9.23 CITED2 EGLN1 EP300 EPAS1 HIF1A HIF1AN

Drugs & Therapeutics for Hypoxia

Drugs for Hypoxia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 416)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bosentan Approved, Investigational Phase 4 147536-97-8 104865
2
Succinylcholine Approved Phase 4 306-40-1 5314
3
Atropine Approved, Vet_approved Phase 4 5908-99-6, 51-55-8 174174
4
Terbutaline Approved Phase 4 23031-25-6 5403
5
Ipratropium Approved, Experimental Phase 4 60205-81-4, 22254-24-6 43232 657309
6
Fluticasone Approved, Experimental Phase 4 90566-53-3 62924
7
Nebivolol Approved, Investigational Phase 4 152520-56-4, 118457-14-0, 99200-09-6 71301
8
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
9
Bisoprolol Approved Phase 4 66722-44-9 2405
10
Methazolamide Approved Phase 4 554-57-4 5353756 4100
11
Cetirizine Approved Phase 4 83881-51-0 2678
12
Histamine Approved, Investigational Phase 4 51-45-6, 75614-87-8 774
13
Alprostadil Approved, Investigational Phase 4 745-65-3 149351 5280723
14
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
15
Losartan Approved Phase 4 114798-26-4 3961
16
Alfentanil Approved, Illicit Phase 4 71195-58-9 51263
17
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
18
Doxapram Approved, Vet_approved Phase 4 309-29-5 3156
19
tannic acid Approved Phase 4 1401-55-4
20
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
21
Trazodone Approved, Investigational Phase 4 19794-93-5 5533
22
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
23
Acetazolamide Approved, Vet_approved Phase 4 59-66-5 1986
24
Amlodipine Approved Phase 4 88150-42-9 2162
25
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 11128-99-7, 4474-91-3 172198
26
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
27
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
28
Creatine Approved, Investigational, Nutraceutical Phase 4 57-00-1 586
29
Cysteine Approved, Nutraceutical Phase 4 52-90-4 5862
30
Maleic acid Experimental Phase 4 110-16-7 444266
31 Albuterol Phase 4
32 insulin Phase 4
33 Insulin, Globin Zinc Phase 4
34 Mydriatics Phase 4
35 Ether Phase 4
36 Liver Extracts Phase 4
37 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
38 Parasympatholytics Phase 4
39 Muscarinic Antagonists Phase 4
40 Cholinergic Agents Phase 4
41 Cholinergic Antagonists Phase 4
42
Salmeterol xinafoate Phase 4 94749-08-3 56801
43 Tiotropium Bromide Phase 4 136310-93-5
44
Beclomethasone Phase 4 4419-39-0 20469
45 Excitatory Amino Acid Antagonists Phase 4
46 Central Nervous System Stimulants Phase 4
47 Anti-Arrhythmia Agents Phase 4
48 Adrenergic alpha-1 Receptor Antagonists Phase 4
49 Adrenergic beta-Antagonists Phase 4
50 Sympatholytics Phase 4

Interventional clinical trials:

(show top 50) (show all 989)
# Name Status NCT ID Phase Drugs
1 The Effects of Hyperoxia on Organ Dysfunction and Outcome in Critically Ill Patients With SIRS Unknown status NCT02321072 Phase 4 Oxygen
2 Sevoflurane-based Volatile Induction and Maintenance of Anaesthesia (VIMA) Strategy Decreases the Risk of Postoperative Delirium in Elderly Patients With Registered Cerebral Hypoxemia Episodes During General Surgery Unknown status NCT02133638 Phase 4 Sevoflurane;Propofol
3 Comparison of Efficacy Different Treatment Regimens in Pulmonary Hypertension Secondary to Lung Disease and or Hypoxia Unknown status NCT01449253 Phase 4 Sildenafil;Bosentan
4 Atropine Versus no Atropine for Neonatal Rapid Sequence Intubation Unknown status NCT01595399 Phase 4 atropine;Placebo
5 Long-Term Oxygen Therapy (LTOT) in Chronic Obstructive Pulmonary Disease (COPD) Patients With Moderate Chronic Hypoxemia and Chronic Heart Failure (CHF) Unknown status NCT00668408 Phase 4
6 Continuous Positive Airway Pressure for Treatment of Postoperative Hypoxemia in Liver Transplant Unknown status NCT00510770 Phase 4
7 Hypoventilation and High Altitude Chronic Polycythemia: Acetazolamide as a Possible Treatment Completed NCT00424970 Phase 4 acetazolamide
8 Nasal Budesonide in Children With Rhinitis and/or Mild Obstructive Sleep Apnea Syndrome Completed NCT00560586 Phase 4 Budesonide;placebo
9 Continuous Positive Airway Pressure (CPAP) and Acetazolamide for Treatment of Patients With the Obstructive Sleep Apnea Syndrome at Altitude Completed NCT00928655 Phase 4 acetazolamide;placebo
10 Comparison of the Cardiovascular, Metabolic and Respiratory Effects of Nebivolol and Carvedilol at High Altitude in Healthy Subjects. Completed NCT00924833 Phase 4 placebo;Carvedilol;Nebivolol
11 Effect of Systemic Hypoxia and Hyperoxia on Retinal Oxygen Saturation Completed NCT01692821 Phase 4 100% oxygen breathing;15% oxygen in N2 breathing;12% oxygen in N2 breathing
12 Nebivolol Versus Bisoprolol Versus Carvedilol in Heart Failure: Effects on Exercise Capacity and Hypoxia, Chemoreceptor Response, Pulmonary Function Completed NCT00517725 Phase 4 carvedilol;bisoprolol;Nebivolol
13 Hyperoxia: An Unrecognized Mechanism for Inducing "Hypoxia-Like" Symptoms Completed NCT03268590 Phase 4 Oxygen
14 Bispectral Index and Clinical Parameters Evaluation in Different Dental Procedures With Nitrous Oxide and Oxygen Sedation Completed NCT02671578 Phase 4 Nitrous Oxide
15 Acute Ventilatory Response to Hypoxia During Sedation With Dexmedetomidine Compared to Propofol in Healthy Male Volunteers Completed NCT01873612 Phase 4
16 The Effect of Carbonic Anhydrase Inhibitors on the Pulmonary System Response to Muscle Fatigue. Completed NCT02758470 Phase 4 Acetazolamide;Methazolamide
17 Effect of an H1 Receptor Antagonist on Exercise Performance in Hypoxia Completed NCT03192488 Phase 4 Cetirizine;Placebo oral capsule
18 5-hydroxytryptophan and Creatine for Treatment Resistant Depression Associated With Hypoxia in Females Completed NCT02356107 Phase 4 5-hydroxytryptophan and Creatine monohydrate
19 The Effect of Carbonic Anhydrase Inhibitors on the Pulmonary System Response to Hypoxia Completed NCT02760121 Phase 4 Acetazolamide;Methazolamide;Placebo
20 GlitazOne Treatment for Coronavirus HypoxiA, a Safety and Tolerability Open Label With Matching Cohort Pilot Study Completed NCT04473274 Phase 4 Pioglitazone
21 Lipo-prostaglandin E1 Improves Renal Hypoxia Evaluated by BOLD-MRI in Patients Completed NCT02628106 Phase 4 Lipo-PGE1
22 Can Muscle Dysfunction in COPD be Altered by Oxygenation in Patients With Intermittent Hypoxia on Exertion? Completed NCT01722370 Phase 4 Oxygen;Medical air equivalent
23 Effect of Angiotensin Receptor Blockers on Periodic Breathing During Sleep in Hypoxia Completed NCT03335904 Phase 4 Losartan;Placebo
24 The Optimal Regimen of Alfentanil in Propofol Sedative Fibro-bronchoscopy:a Prospective Randomized, Double-blind, Placebo-controlled Trial Completed NCT01470170 Phase 4 Alfentanil;Normal saline;Propofol
25 Early Nasal High Flow Oxygen Therapy for Prevention of Postoperative Hypoxemia After Abdominal Surgery: A Multicenter Randomized Controlled Trial Completed NCT01887015 Phase 4
26 Preoxygenation Using Noninvasive Ventilation Prior Intubation in Hypoxemic Patients Completed NCT00472160 Phase 4
27 Ketamine Effect on Recovery and Respiratory Outcomes After Laparoscopic Gastric Reduction: A Randomized, Double-Blinded, Placebo Controlled Study Completed NCT01997515 Phase 4 Ketamine;placebo
28 Acute Effects of Sodium-glucose Cotransporter-2 Inhibition on Renal Oxygenation and Autonomic Function in Type 1 Diabetes Completed NCT04193566 Phase 4 Forxiga
29 Doxapram as an Additive to Propofol Sedation in Sedation for Endoscopic Retrograde Cholangiopancreatography Completed NCT02171910 Phase 4 Doxapram;Placebo
30 Acute Effect of Indacaterol Maleate on Static and Dynamic Lung Volume in COPD Subjects. Completed NCT01377051 Phase 4 Indacaterol maleate;Placebo
31 Recruitment Maneuver Increases Oxygenation After Intubation in Hypoxemic ICU Patients: a Randomized Controlled Study Completed NCT01014299 Phase 4
32 The Effect of Nasal Cannula During the First 2 Hours Postoperative in Patient Undergoing Thoracotomy Completed NCT01725464 Phase 4
33 Reducing the Need for Intensive Care Unit in Hospitalized Patients With Early Respiratory Failure Using the Non-invasive Ventilation Technique. A Multicentre Randomized Study. Recruiting NCT01572337 Phase 4
34 Treatment of Sleep Apnea in Patients With Cervical Spinal Cord Injury Recruiting NCT02922894 Phase 4 Trazodone;Placebo
35 REgistry-based Randomized Controlled Trial of Treatment Duration and Mortality in Long-term OXygen Therapy (REDOX) A Multicenter, Phase IV, Registry-Based, Randomized Controlled Trial (R-RCT) Recruiting NCT03441204 Phase 4 LTOT 24 h/day;LTOT 15h/day
36 A Randomized, Double-blind, Placebo-controlled Trial of 5-hydroxytryptophan and Creatine for SSRI or SNRI Augmentation in Treatment Resistant Depression Associated With Hypobaric Hypoxia in Females Recruiting NCT02922725 Phase 4 5-hydroxytryptophan and Creatine
37 Impact of High-flow Nasal Cannula Oxygen (HFNC) Versus Noninvasive Ventilation Associated With Sleep Quality on Atrial Fibrillation in Hypoxemic Patients After Coronary Surgery Recruiting NCT02713737 Phase 4
38 Effect of Dexmedetomidine on Brain Homeostasis and Neurocognitive Outcome of Patients Undergoing Brain Tumor Exclusion Recruiting NCT04266665 Phase 4 Dexmedetomidine
39 Addition of Neuromuscular-Blocking Agents During Sevoflurane Induction in Infants : Potential Interest in Reducing Hypoxemia Episodes Recruiting NCT02589691 Phase 4 Rocuronium
40 Phase 4, Randomized, Placebo-controlled, Cross-over Trial to Assess the Effect of 4-week Ertugliflozin (SGLT-2 Inhibitor) Therapy on Renal Oxygenation by BOLD-MRI and Renal Oxygen Consumption by PET Using ¹¹C-acetate in T2DM Without Kidney Disease and Healthy Controls. Recruiting NCT04027530 Phase 4 Ertugliflozin 15 mg
41 Effect of Acetazolamide on Right Heart Function at Rest in Lowlanders Older Than 40 Years at Altitude.: A Randomized, Placebo-controlled, Double-blind Parallel Trial Active, not recruiting NCT03540914 Phase 4 ACETAZOLAMIDE oral capsule;Placebo oral capsule
42 Effect of Acetazolamide on Right Heart Function During Exercise in Lowlanders Older Than 40 Years at Altitude: A Randomized, Placebo-controlled, Double-blind Parallel Trial Active, not recruiting NCT03537924 Phase 4 ACETAZOLAMIDE oral capsule;Placebo oral capsule
43 Effect of Acetazolamide on Lung Water Content by Ultrasound in Lowlanders Older Than 40 Years at Altitude: A Randomized, Placebo-controlled, Double-blind Parallel Trial Active, not recruiting NCT03539367 Phase 4 ACETAZOLAMIDE oral capsule;Placebo oral capsule
44 Effect of Acetazolamide on Visuo-motor Learning in Lowlanders Older Than 40 Years at Altitude: A Randomized, Placebo-controlled, Double-blind Parallel Trial Active, not recruiting NCT03536520 Phase 4 ACETAZOLAMIDE oral capsule;Placebo oral capsule
45 Effect of Acetazolamide on Sleep Disordered Breathing in Lowlanders Older Than 40 Years at Altitude: A Randomized, Placebo-controlled, Double-blind Parallel Trial Active, not recruiting NCT03536507 Phase 4 ACETAZOLAMIDE oral capsule;Placebo oral capsule
46 Effect of Acetazolamide on Maximal Exercise Performance in Lowlanders Older Than 40 Years at Altitude: A Randomized, Placebo-controlled, Double-blind Parallel Trial Active, not recruiting NCT03536455 Phase 4 ACETAZOLAMIDE oral capsule;Placebo oral capsule
47 Effect of Acetazolamide on Postural Control in Lowlanders Older Than 40 Years at Altitude: A Randomized, Placebo-controlled, Double-blind Parallel Trial Active, not recruiting NCT03536429 Phase 4 ACETAZOLAMIDE oral capsule;Placebo oral capsule
48 Cardiovascular and Metabolic Physiological Adaptations to Intermittent Hypoxia. Physiological Aspects and Expression of Receptors and Cellular Mediators Terminated NCT02058823 Phase 4 Placebo;Placebo;Valsartan;Amlodipine
49 Non-Invasive Ventilation in Early Severe Posttraumatic Hypoxia: a Randomized Controlled Trial Terminated NCT00557752 Phase 4
50 Modulation of Oxygen Sensor Reactivity to Mimic Altitude Acclimatization Terminated NCT01241513 Phase 4 NAC;Placebo

Search NIH Clinical Center for Hypoxia

Genetic Tests for Hypoxia

Anatomical Context for Hypoxia

MalaCards organs/tissues related to Hypoxia:

40
Endothelial, Smooth Muscle, Prostate, Brain, Bone Marrow, Skeletal Muscle, Cortex

Publications for Hypoxia

Articles related to Hypoxia:

(show top 50) (show all 30000)
# Title Authors PMID Year
1
Increased expression of hypoxia-induced factor 1α mRNA and its related genes in myeloid blood cells from critically ill COVID-19 patients. 61
33345622 2021
2
Hypoxia response element-directed expression of bFGF in dental pulp stem cells improve the hypoxic environment by targeting pericytes in SCI rats. 61
33553827 2021
3
Role of dehydroepiandrosterone sulfate as a scavenging antioxidant: the evidence from Caenorhabditis elegans' nervous system under hypoxia. 61
33433471 2021
4
Investigating the link between Pearl River-induced eutrophication and hypoxia in Hong Kong shallow coastal waters. 61
33581521 2021
5
TP53-induced glycolysis and apoptosis regulator alleviates hypoxia/ischemia-induced microglial pyroptosis and ischemic brain damage. 61
33269748 2021
6
In vitro temporal HIF-mediated deposition of osteochondrogenic matrix governed by hypoxia and osteogenic factors synergy. 61
33151579 2021
7
Functional role of carbon dioxide on intermittent hypoxia induced respiratory response following mid-cervical contusion in the rat. 61
33453216 2021
8
Effect of acute intermittent hypoxia on cortico-diaphragmatic conduction in healthy humans. 61
33607080 2021
9
Mitochondria antioxidant protection against cardiovascular dysfunction programmed by early-onset gestational hypoxia. 61
33788974 2021
10
An integrated model to predict and prevent hypoxia in floodplain-river systems. 61
33684798 2021
11
Overexpression of STAT4 under hypoxia promotes EMT through miR-200a/STAT4 signal pathway. 61
33636177 2021
12
in vivo Monitoring with micro-implantable hypoxia sensor based on tissue acidosis. 61
33676640 2021
13
Small extracellular vesicles containing miR-192/215 mediate hypoxia-induced cancer-associated fibroblast development in head and neck squamous cell carcinoma. 61
33639203 2021
14
Role of hypoxia‑inducible factor‑2α in lung cancer (Review). 61
33760175 2021
15
Differential Age-Dependent Mitochondrial Dysfunction, Oxidative Stress, and Apoptosis Induced by Neonatal Hypoxia-Ischemia in the Immature Rat Brain. 61
33417220 2021
16
Pregnancy swimming prevents early brain mitochondrial dysfunction and causes sex-related long-term neuroprotection following neonatal hypoxia-ischemia in rats. 61
33529673 2021
17
The individual and combined effects of hypoxia and high-fat diet feeding on nutrient composition and flesh quality in Nile tilapia (Oreochromis niloticus). 61
33143967 2021
18
JTZ-951 (enarodustat), a hypoxia-inducible factor prolyl hydroxylase inhibitor, improves iron utilization and anemia of inflammation: Comparative study against recombinant erythropoietin in rat. 61
33657422 2021
19
SK channel blockade prevents hypoxia-induced ventricular arrhythmias through inhibition of Ca2+/voltage uncoupling in hypertrophied hearts. 61
33635168 2021
20
Hypoxia-Like Events in UK Typhoon Aircraft from 2008 to 2017. 61
33752789 2021
21
Ameliorative Effect of Ananas comosus on Cobalt Chloride-Induced Hypoxia in Caco2 cells via HIF-1α, GLUT 1, VEGF, ANG and FGF. 61
32654099 2021
22
Trimetazidine alleviates hypoxia/reoxygenation-induced apoptosis in neonatal mice cardiomyocytes via up-regulating HMGB1 expression to promote autophagy. 61
32757698 2021
23
MicroRNA-210 Mediates Hypoxia-Induced Repression of Spontaneous Transient Outward Currents in Sheep Uterine Arteries During Gestation. 61
33641365 2021
24
The middle cerebral artery blood velocity response to acute normobaric hypoxia occurs independently of changes in ventilation in humans. 61
33527604 2021
25
Lymphocyte Infiltration Determines the Hypoxia-Dependent Response to Definitive Chemoradiation in Head-and-Neck Cancer: Results from a Prospective Imaging Trial. 61
32859699 2021
26
Intermittent hypercapnic hypoxia: a model to study human respiratory motor plasticity? 61
33480443 2021
27
Gait asymmetries during perceptually-regulated interval running in hypoxia and normoxia. 61
33792523 2021
28
Distributive stress: individually variable responses to hypoxia expands trophic niches in fish. 61
33811651 2021
29
The optimization conditions of establishing an H9c2 cardiomyocyte hypoxia/reoxygenation injury model based on an AnaeroPack System. 61
33289183 2021
30
Correction to: Effects of acute hypoxia on human adipose tissue lipoprotein lipase activity and lipolysis. 61
33794914 2021
31
Contribution of the offshore detached Changjiang (Yangtze River) Diluted Water to the formation of hypoxia in summer. 61
33757237 2021
32
Correction: A Hypoxia-Inducible HIF1-GAL3ST1-Sulfatide Axis Enhances ccRCC Immune Evasion via Increased Tumor Cell-Platelet Binding. 61
33811174 2021
33
Real-time monitoring hypoxia at high altitudes using electrical bioimpedance technique: an animal experiment. 61
33270508 2021
34
Identification of differentially expressed genes in mouse embryonic stem cell under hypoxia. 61
33094376 2021
35
Effects of hypoxia on the respiratory and metabolic responses to progressive cooling in newborn rodents that range in heterothermic expression. 61
33608952 2021
36
Reversal of neurovascular coupling in the default mode network: Evidence from hypoxia. 61
32538282 2021
37
Hypoxia-inducible factor activity promotes antitumor effector function and tissue residency by CD8+ T cells. 61
33792560 2021
38
Independent and combined impact of hypoxia and acute inorganic nitrate ingestion on thermoregulatory responses to the cold. 61
33558988 2021
39
The tolerance to hypoxia is defined by a time-sensitive response of the gene regulatory network in sea urchin embryos. 61
33795230 2021
40
Hypoxia-inducible factor-2α mediates senescence-associated intrinsic mechanisms of age-related bone loss. 61
33811248 2021
41
Correction to: Longitudinal PET Imaging to Monitor Treatment Efficacy by Liposomal Irinotecan in Orthotopic Patient-Derived Pancreatic Tumor Models of High and Low Hypoxia. 61
33398716 2021
42
Hypoxia-mediated drug resistance in breast cancers. 61
33278499 2021
43
Combined hypoxia and high temperature affect differentially the response of antioxidant enzymes, glutathione and hydrogen peroxide in the white shrimp Litopenaeus vannamei. 61
33465469 2021
44
Carbohydrate Supplementation and the Influence of Breakfast on Fuel Use in Hypoxia. 61
33044437 2021
45
Medullary and Hypothalamic Functional Magnetic Imaging During Acute Hypoxia in Tracing Human Peripheral Chemoreflex Responses. 61
33641354 2021
46
Hypoxia up-regulates VEGF ligand and downregulates VEGF soluble receptor mRNA expression in bovine granulosa cells in vitro. 61
33640589 2021
47
Astragaloside IV improves angiogenesis under hypoxic conditions by enhancing hypoxia‑inducible factor‑1α SUMOylation. 61
33537820 2021
48
Metabolic adaptation in hypoxia and cancer. 61
33444690 2021
49
Double whammy: Nitrate pollution heightens susceptibility to both hypoxia and heat in a freshwater salmonid. 61
33077222 2021
50
High-altitude hypoxia induced reactive oxygen species generation, signaling, and mitigation approaches. 61
33156424 2021

Variations for Hypoxia

Expression for Hypoxia

Search GEO for disease gene expression data for Hypoxia.

Pathways for Hypoxia

Pathways related to Hypoxia according to GeneCards Suite gene sharing:

(show all 21)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.25 VHL VEGFA PSMA7 HIGD1A HIF3A HIF1AN
2 12.86 VHL VEGFA HIF1A EPAS1 EP300 EGLN3
3
Show member pathways
12.64 VHL VEGFA HIF1A EPAS1 EP300 EGLN3
4
Show member pathways
12.45 VHL VEGFA PSMA7 HIGD1A HIF3A HIF1AN
5 12.27 HIF1AN HIF1A EPAS1 EGLN1 CA9 ARNT
6 12.01 VHL VEGFA HIF1A EP300 EGLN3 EGLN2
7
Show member pathways
11.89 VHL VEGFA HIF1A EPAS1 ARNT
8 11.88 HIF1AN HIF1A EP300 EGLN1 CA9 ARNT
9
Show member pathways
11.74 VEGFA EP300 CITED2
10
Show member pathways
11.69 VEGFA HIF1A EP300 ARNT
11 11.67 VEGFA HIF1A EP300 EGLN3 EGLN1 CITED2
12 11.54 VHL VEGFA PSMA7 HIF1AN HIF1A EP300
13 11.46 VEGFA HIF1AN HIF1A EGLN1 ARNT
14 11.45 HIF1A EP300 ARNT
15 11.44 VEGFA EP300 ARNT
16
Show member pathways
11.42 HIF1AN HIF1A EPAS1 EP300 EGLN3 CITED2
17 11.19 VHL VEGFA HIF1AN EPAS1 EP300 EGLN3
18 11.12 VEGFA HIF1A ARNT
19 10.98 VHL HIF3A HIF1AN HIF1A ARNT
20 10.96 VHL VEGFA EPAS1
21 10.67 VEGFA HIF1AN HIF1A

GO Terms for Hypoxia

Cellular components related to Hypoxia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytosol GO:0005829 10.1 VHL TIGAR PSMA7 KMT2A HILPDA HIF3A
2 cytoplasm GO:0005737 10.1 VHL VEGFA TIGAR PSMA7 HIF3A HIF1AN
3 nucleus GO:0005634 9.83 VHL TIGAR PSMA7 KMT2A HIF3A HIF1AN
4 nucleoplasm GO:0005654 9.47 VHL PSMA7 KMT2A HILPDA HIGD1A HIF3A
5 transcription factor complex GO:0005667 9.46 HIF1A EPAS1 EP300 ARNT

Biological processes related to Hypoxia according to GeneCards Suite gene sharing:

(show all 25)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.11 VEGFA KMT2A HIF1A EPAS1 EP300 CITED2
2 regulation of transcription, DNA-templated GO:0006355 10.1 VHL KMT2A HIF3A HIF1A EPAS1 EP300
3 oxidation-reduction process GO:0055114 10.03 P4HTM HIGD1A HIF1AN EGLN3 EGLN2 EGLN1
4 positive regulation of transcription, DNA-templated GO:0045893 10.02 VHL KMT2A HIF1A EP300 CITED2 ARNT
5 negative regulation of gene expression GO:0010629 9.92 VHL VEGFA HIF1A CITED2
6 negative regulation of apoptotic process GO:0043066 9.91 VHL VEGFA HYOU1 HIGD1A HIF1A CITED2
7 angiogenesis GO:0001525 9.89 VEGFA HIF3A HIF1A EPAS1
8 post-translational protein modification GO:0043687 9.88 VHL PSMA7 HIF3A HIF1A EPAS1
9 cellular response to hypoxia GO:0071456 9.81 VEGFA TIGAR HYOU1 HILPDA HIF1A EPAS1
10 lung development GO:0030324 9.78 VEGFA EPAS1 EP300
11 positive regulation of endothelial cell proliferation GO:0001938 9.76 VEGFA HIF1A ARNT
12 response to hypoxia GO:0001666 9.7 VEGFA HIF3A HIF1A EPAS1 EP300 EGLN3
13 outflow tract morphogenesis GO:0003151 9.69 VEGFA HIF1A CITED2
14 embryonic hemopoiesis GO:0035162 9.62 KMT2A HIF1A
15 embryonic placenta development GO:0001892 9.62 HIF1A EPAS1 CITED2 ARNT
16 positive regulation of vascular endothelial growth factor receptor signaling pathway GO:0030949 9.61 HIF1A ARNT
17 surfactant homeostasis GO:0043129 9.6 VEGFA EPAS1
18 oxygen homeostasis GO:0032364 9.58 HIF1A EGLN1
19 regulation of transcription from RNA polymerase II promoter in response to oxidative stress GO:0043619 9.58 HIF1A EPAS1 ARNT
20 peptidyl-proline hydroxylation to 4-hydroxy-L-proline GO:0018401 9.56 P4HTM EGLN3 EGLN2 EGLN1
21 regulation of protein neddylation GO:2000434 9.54 HIF1A EPAS1
22 negative regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061428 9.54 VHL HIF1AN CITED2
23 positive regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061419 9.52 VEGFA HIF1A
24 regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061418 9.47 VHL VEGFA PSMA7 HIGD1A HIF3A HIF1AN
25 positive regulation of hormone biosynthetic process GO:0046886 9.46 HIF1A ARNT

Molecular functions related to Hypoxia according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 oxidoreductase activity GO:0016491 9.92 P4HTM HIF1AN EGLN3 EGLN2 EGLN1
2 transcription factor binding GO:0008134 9.89 VHL HIF1A EPAS1 EP300 ARNT
3 protein dimerization activity GO:0046983 9.81 HIF3A HIF1A EPAS1 ARNT
4 iron ion binding GO:0005506 9.76 P4HTM EGLN3 EGLN2 EGLN1
5 dioxygenase activity GO:0051213 9.72 P4HTM HIF1AN EGLN3 EGLN2 EGLN1
6 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen GO:0016705 9.71 P4HTM EGLN3 EGLN2 EGLN1
7 histone acetyltransferase binding GO:0035035 9.61 HIF1A EPAS1 CITED2
8 ferrous iron binding GO:0008198 9.56 HIF1AN EGLN3 EGLN2 EGLN1
9 peptidyl-proline dioxygenase activity GO:0031543 9.54 EGLN3 EGLN2 EGLN1
10 oxygen sensor activity GO:0019826 9.48 HIF1AN EGLN2
11 peptidyl-proline 4-dioxygenase activity GO:0031545 9.33 EGLN3 EGLN2 EGLN1
12 L-ascorbic acid binding GO:0031418 9.26 P4HTM EGLN3 EGLN2 EGLN1
13 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, 2-oxoglutarate as one donor, and incorporation of one atom each of oxygen into both donors GO:0016706 9.02 P4HTM HIF1AN EGLN3 EGLN2 EGLN1

Sources for Hypoxia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....